<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378960</url>
  </required_header>
  <id_info>
    <org_study_id>OBS-2011/001</org_study_id>
    <nct_id>NCT03378960</nct_id>
  </id_info>
  <brief_title>Study to Compare the Bioavailability of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity</brief_title>
  <acronym>OBS-2011/001</acronym>
  <official_title>Bioavailability Study of Omeprazole (20 mg) at Steady State (Multiple Dose) in Patients Who Have Undergone Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emilio Vargas Castrillón</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Mutua Madrileña</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim was to evaluate whether gastric bypass surgery modifies the bioavailability&#xD;
      of omeprazole 20 mg at one month and six months after surgery.&#xD;
&#xD;
      Other objectives were:&#xD;
&#xD;
        -  To compare bioavailability of omeprazole 20 mg between patients undergo gastric bypass&#xD;
           surgery and patients who avoid it.&#xD;
&#xD;
        -  To asses other pharmacokinetic parameters, demographic parameters and drug safety.&#xD;
&#xD;
      Study design It was planned a mixed design which intended to compare the bioavailability in&#xD;
      patients with gastric bypass (before and after surgery) and control subjects matched by sex&#xD;
      and body mass index (BMI) post-surgery. This was a single-dose, open-label, crossover&#xD;
      bioavailability study of omeprazole in surgical group and controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2014</start_date>
  <completion_date type="Actual">February 29, 2016</completion_date>
  <primary_completion_date type="Actual">December 23, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This was a single-dose, open-label, bioavailability study of surgical group and controls.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC variation Pharmacokinetic parameters</measure>
    <time_frame>Baseline and 6 month after bariatric surgery</time_frame>
    <description>Omeprazole Biodisponibility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax variation</measure>
    <time_frame>Baseline and 6 month after bariatric surgery</time_frame>
    <description>Time required to reach the maximum concentration of Omeprazole in blood after its administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax variation</measure>
    <time_frame>Baseline and 6 month after bariatric surgery</time_frame>
    <description>Maximum concentration of Omeprazole in blood after its administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC 1 month</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Omeprazole Biodisponibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax 1 month</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Time required to reach the maximum concentration of Omeprazole in blood after its administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax 1 month</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>Maximum concentration of Omeprazole in blood after its administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Bariatric Surgery Candidate</condition>
  <arm_group>
    <arm_group_label>omeprazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>omeprazole 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole 20mg</intervention_name>
    <arm_group_label>omeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who wish to participate in the study (men and women) after receiving adequate&#xD;
             information about the study design, objectives and risks by signing and date of the&#xD;
             written informed consent.&#xD;
&#xD;
          -  Age between 18 and 60 years old.&#xD;
&#xD;
          -  Patients who come to the endocrinology and nutrition Service and on treatment with&#xD;
             omeprazole.&#xD;
&#xD;
          -  Patients who are to undergo bariatric surgery (Roux en Y gastric bypass) according to&#xD;
             the recommendations of Endocrinology and Nutrition Service and the Department of&#xD;
             General Surgery and Digestive Diseases hospital Clinico San Carlos.&#xD;
&#xD;
          -  No significant abnormalities on clinical examination and laboratory analysis before&#xD;
             inclusion in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any postoperative complication that interferes with the regular intake of medication&#xD;
             such as stenosis of anastomotic, fistula, persistent vomiting, diarrhea (&gt; 4 stools&#xD;
             per day), evidence of protein malnutrition (albumin &lt;3.5 g / l).&#xD;
&#xD;
          -  High consumption of stimulating beverages (equivalent to 400 mg of caffeine per day, a&#xD;
             cup of coffee contains approximately 100 mg of caffeine).&#xD;
&#xD;
          -  Consumption of any medication that may interfere with the objectives of the study: *&#xD;
             Use of enzyme inhibitors or inducers within 2 weeks prior to study inclusion&#xD;
             (barbiturates, carbamazepine, erythromycin, phenytoin, oral contraceptives, etc.) *&#xD;
             Any concomitant medication will be assessed by the investigator based on data recorded&#xD;
             in the log-book for the medication (potential interactions) and registered in the CRF.&#xD;
&#xD;
          -  History of clinically significant disease in the opinion of the investigator does not&#xD;
             allow safe participation of the patient.&#xD;
&#xD;
          -  Inability to relate to and / or cooperate with investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fundacion para Investigación Biomedica Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Emilio Vargas Castrillón</investigator_full_name>
    <investigator_title>Head of Clinical Pharmacology Department</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

